These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [TKI therapy for CML]. Ohnishi K Rinsho Ketsueki; 2011 Jul; 52(7):452-9. PubMed ID: 21821976 [No Abstract] [Full Text] [Related]
8. Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O]. Kantarjian H Clin Adv Hematol Oncol; 2008 Nov; 6(11):797-9. PubMed ID: 19194361 [No Abstract] [Full Text] [Related]
9. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure. Hochhaus A Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968 [TBL] [Abstract][Full Text] [Related]
10. 10 years of progress in chronic myelogenous leukemia. Jabbour E; Mathisen MS; O'Brien S J Natl Compr Canc Netw; 2012 Sep; 10(9):1049-53. PubMed ID: 22956803 [No Abstract] [Full Text] [Related]
11. Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib. Loglisci G; Breccia M; Nanni M; Mancini M; De Cuia R; Cannella L; Salaroli A; Federico V; Serrao A; Loglisci MG; Santopietro M; Alimena G Leuk Lymphoma; 2011 Jul; 52(7):1372-5. PubMed ID: 21463110 [No Abstract] [Full Text] [Related]
15. Dasatinib: is it all in the dose? Condorelli F; Genazzani AA BioDrugs; 2010 Jun; 24(3):157-63. PubMed ID: 20222756 [TBL] [Abstract][Full Text] [Related]